Clustering of longitudinal viral loads in the Western Cape by Arua, Eke Nnanna
UNIVERSITY OF CAPE TOWN 
Clustering of longitudinal viral loads in the Western Cape 
Eke Nnanna Arua 
ARXEKE001 
Dissertation submitted in partial fulfilment of the requirements for the degree 
MASTER OF PUBLIC HEALTH in Epidemiology 
in the 
School of Public Health & Family Medicine 
Supervisors: Associate Professor Maia Lesosky 




















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 


















I, Eke Nnanna Arua (ARXEKE001), hereby declare that the work on which this dissertation/thesis is based 
is my original work (except where acknowledgements indicate otherwise) and that neither the whole work 
nor any part of it has been, is being, or is to be submitted for another degree in this or any other university. 
I empower the university to reproduce for the purpose of research either the whole or any portion of the 
contents in any manner whatsoever. 
Signature: 
Date:   10 February 2020 




I would like to thank my supervisor Associate Professor Maia Lesosky for her invaluable guidance and 
encouragement throughout this dissertation and the MPH in general. You continue to be a great source 
of inspiration for me.  
To my co-supervisor Professor Landon Myer, I appreciate your input and your constant words of 
encouragement as we approached the final stages of this dissertation. 
To Lilian, Jeff, Anathi, Phindi and my better half Ndiphe; I would not have made it this far without your 
words of motivation and support. 
Finally, to my Family, this is one is for you! 
  
   
iv 
 
3. Thesis abstract 
Introduction: Routine viral load (VL) monitoring is important for assessing the effectiveness of ART in 
South Africa. There is little information however, on how the longitudinal VL patterns change for 
subgroups of persons living with HIV (PLHIV) who have experienced at least one elevated VL. We 
investigated the possible longitudinal VL patterns that may exist among this unique population. 
Methods: This mini-dissertation offers three components; a research protocol (Section A), a literature 
review (Section B) and a journal ready manuscript (Section C). We examined HIV VL data for the Western 
Cape from 2008 to 2018, taken from the National Health Laboratory Services (NHLS). Using <1000 
copies/mL as a threshold for viral suppression, we identified 109092 individuals who had at least one 
instance of an elevated VL. A nonparametric (KML-Shape) and a model-based (LCMM) clustering 
technique were used to identify latent subgroups of longitudinal VL trajectories among these individuals. 
Results: Both the KML-Shape and LCMM clustering techniques identified five latent viral load trajectory 
subgroups. KML-Shape found majority of individuals’ trajectories belonged to clusters that had a 
decreasing longitudinal VL trend (76.6% of individuals), while LCMM found a smaller proportion of 
individuals’ trajectories belonged to clusters that had a decreasing longitudinal trend (52.5% of 
individuals). Most of the trajectory subgroups identified had long periods of low-level viremia.  
Conclusion: Although majority of individuals belonged to clusters that had downward trends, further 
research is needed to better understand factors contributing to membership of clusters that did not have 
a downward longitudinal trend. Understanding these factors may help in the development of targeted 
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Technological advancements have led to collection of large amounts of data as part of routine health care. 
Commonly, these data sources are often re-purposed for use in medical and health research. These data 
are usually stored in data sets that either contain; a large number of rows (observations), a large number 
of columns (variables), or both. For such large datasets, exploratory data analysis is an important approach 
for discovering relationships and patterns in the data. It is common for these data sets to contain 
multivariate data. Analyzing multivariate data in large quantities often present difficulties in analytic 
methodology and data interpretation.1 Categorizing and labeling clusters of similar objects is important 
for summarizing  large datasets so that a concise description of patterns of similarities and differences in 
the data can be provided.2 
Cluster analysis is an important data exploration tool that can be used for determining patterns in 
multivariate data and is used in many disciplines ranging from biology, statistics, economics and 
marketing.3 Cluster analysis attempts to separate objects into homogenous groups so that objects within 
groups are similar to each other but different to objects in other groups. In the field of health, it can be 
used to discover patient subgroups defined by differing characteristics. This may have several advantages 
such as; the development or improvement of diagnostic criteria, better understanding of heterogeneous 
outcomes, and adapting treatments to better suit patient profiles.4  
Cluster analysis can and has been applied to human immunodeficiency virus (HIV) research in various 
ways.5-7 The chronic nature of HIV in the era of effective antiretroviral treatment means that there can be 
considerable heterogeneity in disease management and progression amongst persons living with HIV 
(PLHIV). Long term suppression of HIV viral load (VL) is known to help reduce HIV incidence by preventing 
transmission of HIV from person to person, as well as being associated with better health outcomes.8 In 
many health systems, VL is monitored routinely, and it is of interest, at both a population and individual 
level, to understand the trajectories of viral suppression over time. Cluster analysis can be applied to HIV 
VL data specifically and has previously provided insights in grouping patients according to their 
longitudinal viral load patterns.9 There are several methods available to cluster longitudinal series which 
can be applied to repeated VL measurements. From a public health standpoint, it may be pertinent to 
identify different longitudinal VL patterns amongst PLHIV, especially those related to adverse health 
outcomes and to understand risk factors that are associated with these patterns. Understanding how and 
why PLHIV VLs change over time could lead to improved targeted HIV programs. 
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This work will apply and compare existing methods for clustering longitudinal trajectories to a data set of 
routine VL measurements from the Western Cape, South Africa.  
1.1 Background of study 
The high burden of HIV/AIDs remains a major public health issue in South Africa. As of 2017, the 
prevalence of HIV in the country was estimated to be one of the highest in the world at approximately 
14%.10 In 2011, the estimated proportion of direct and indirect deaths due to HIV/AIDS was 43.6%; which 
was a decline from previous years but remains unacceptably high.11 Interventions aimed at reducing HIV-
related mortality are crucial and their successful implementation will not only ease the direct burden 
caused by HIV but also improve the prevention and management of colliding epidemics, such as rising 
rates of diabetes.  
With respect to tackling HIV-related mortality, antiretroviral therapy (ART) is the primary intervention for 
HIV infected persons. South Africa’s treatment programme is the largest globally, accounting for 20% of 
people on ART worldwide.12 Since the advent of ART in 2004, there has been a great improvement in the 
mortality rate of HIV infected persons in the country.13,14 The life expectancies of South African adults 
living with HIV are comparable to those who do not have HIV provided they initiate ART early.15 The Joint 
United Nations Programme on HIV/AIDS (UNAIDS) 2020 targets require that 90% of all  HIV-infected 
persons be diagnosed, 90% of those diagnosed should be on treatment, with at least 90% achieving and 
maintaining viral suppression (90-90-90 targets).16 There has been steady progress towards reaching these 
targets with approximately between 38-54% of all infected persons in the country being virally suppressed 
by 2015, however this is well short of the required 73%.17  
Routine VL monitoring is important for measuring people’s initial and continual response to ART.  It is 
recommended by the World Health Organization (WHO) as the principal method for diagnosis and 
confirmation of treatment failure or virologic suppression for people who are on ART.18 The data that is 
collected from routine VL monitoring is crucial in efforts towards understanding the population viral load 
suppression rates in the country. For example, routine VL data can facilitate the identification of groups 
of unsuppressed individuals that may require additional resources such as enhanced adherence 
counselling (EAC).18  
South African routine VL data – which is longitudinal in nature –  is often used to estimate or offer insights 
on mean population level proportions of ART adherence and virologic suppressions as well as their 
respective longitudinal trends. These analytic approaches are relevant and often yield important results 
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and insights, but they rely on pre-specified subpopulation of individuals such as age groups, race, 
geographic location and sex. Over-reliance on these sub-populations when investigating longitudinal VL 
trajectories hinder our ability to account for unobserved heterogeneity and fully understand both the 
longitudinal pattern and determinants of VL suppression within the population. There may exist 
unobserved sub-populations or categories of longitudinal profiles whose detection could lead to more 
effective and efficient treatment by adapting healthcare and health promotion to better suit peoples’ 
profiles. Within South Africa’s setting, there has been little research investigating whether there exists the 
presence of distinct latent VL trajectories amongst people who have initiated ART. 
1.2 Rationale of the study 
Because of the slow progress towards a 73% VL suppression of all HIV infected persons. South Africa is 
unlikely to achieve its 90-90-90 targets on schedule. Achieving a 90% viral suppression amongst HIV 
infected persons has proven a difficult landmark to reach. To understand the reasons why adequate viral 
suppression rates have not been obtainable so far, novel approaches in the analysis of VL data are 
necessary. In particular, the identification of clinically important sub-populations that have undesirable 
VL trajectories (i.e. trajectories that show an increasing trend after ART initiation) may offer important 
insights for targeted interventions – such as specific health promotion campaigns – and further research. 
The Western Cape routine VL monitoring data affords a unique opportunity to get deeper understandings 
of how different groups of individuals VLs change over time using a more objective approach compared 
to methods that are normally used for longitudinal data.  
2. Study aims and objectives 
2.1 Aims  
This study has two aims. The first aim is to apply and compare methods to cluster longitudinal VL load 
trajectories using routine VL data collected in the Western Cape - a large province in South Africa. The 
second aim is to determine which factors are associated with membership to the identified clustered 
trajectories; particularly, trajectories that are not considered desirable in a public health context.  
2.2 Objectives 
Primary objective: To identify and apply appropriate methods for clustering and classification of 
longitudinal VL trajectories using routine VL data. 
 




1. Describe the clusters of VL trajectory identified and compare them by clustering methods used 
2. Identify and compare for each clustering method used, the risk factors associated with cluster 
membership. 
3. Methodology 
3.1 Study design 
To identify clustered VL trajectories, a secondary data analysis of anonymized individuals’ repeated VL 
measurements from the National Health Laboratory Services (NHLS) in the Western Cape will be used. 
The NHLS is the largest diagnostic pathology service in South Africa. It has laboratories in every province 
in the country and covers 80% of the population.19  In the Western Cape, the NHLS data covers all public 
sector ART services. Records obtained will span a period of 10 years from the year 2008 to 2018.  
3.2 Sampling and Study population 
The nature of this research implies that a sample size calculation is unnecessary as all records available 
from the 10-year period will be used for analysis. Participants to be included in this study are HIV infected 
individuals in the Western Cape who have initiated ART before or during the 10-year period for which 
data was collected and who have had at least one routine viral load monitoring test.  
3.3 Data management 
The data will be anonymized by the parent study data manager so that all identifiable information will be 
removed prior to analysis. Direct identifiers such as names and patient IDs will be removed from the data 
set. A unique identifier that cannot be linked with the original direct identifiers will be generated from the 
data set to assist with analysis. The relevant data will be kept on a password protected computer in the 
school of Public Health and Family Medicine at the University of Cape Town. When not in use, the 
computer will be kept in a locked office with limited access. The statistical software package that will be 
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3.4 Data Analysis 
3.4.1 Clustering 
There are numerous approaches to clustering of longitudinal trajectories. Methods that will be applied 
are summarized below. 
Broadly, most clustering methods can be categorized as either being parametric (model-based) or 
nonparametric. The non-parametric approach makes few assumptions on the distribution of the data 
while the model-based approach assumes data vectors are generated from a finite mixture of specified 
distributions.  
Nonparametric clustering 
This approach to clustering makes few assumptions on the distribution of the data. The number of 
categories, the choice of similarity (or dissimilarity) measure and the clustering algorithm are the major 
components needed for this method.2,20  
Similarity/dissimilarity measure 
Often called a “distance measure”, the similarity or dissimilarity measure is any function d, used to 
measure the distinctiveness between two individuals or objects. The choice of distance measure requires 
careful consideration as it can have a large impact on the clustering results. The underlying logic in cluster 
analysis is that objects belonging to the same cluster are more similar than objects in different clusters.  
Nonparametric clustering algorithms 
These clustering algorithms can generally be grouped as either hierarchical or partitioning algorithms 
depending on the search strategy that is used.3 Partitioning algorithms split the data into k ≥ 2 distinct 
clusters. These clusters must be mutually exclusive and their objects collectively exhaustive. This means 
that there must be at least one object in each cluster and an object cannot belong to more than one 
cluster. The number of clusters, k, is often user-defined (although, there exist computer-based methods 
for determining it).3 Hierarchical clustering techniques rely on constructing trees of clusters, in which the 
root node is a single cluster with all objects (k = 1) and the leaves are clusters that each contain a single 
object (k = n).2,21 There are two types of ways hierarchical clustering can be carried out; in a bottom-up 
manner (agglomerative) or in a top-down manner (divisive). As the names suggest, the two methods 
construct their trees in opposite directions. The divisive method starts when all objects are in a single 
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cluster and are split up in each step until there are n of them. The agglomerative method starts when 
there are n clusters and each step two clusters are merged until there is only one cluster remaining. 
Hierarchical clustering should be used with an a priori scientific understanding of the hierarchical nature 
of the data.2 
A nonparametric approach that will be used in this research is KML-Shape; an extension of KML (k-means 
for longitudinal data) by Genolini and Falissard.22,23 It offers an efficient way to cluster longitudinal data 
on the basis of the shape of their VL trajectories and allows individuals who have different VL trajectory 
forms that have shifted locations in time to be grouped together. It uses a measure of distinctiveness 
between individuals’ trajectories that is based on their shape rather than their level. 
Model-based clustering 
Under the nonparametric clustering approach, each object can only belong to one cluster. This is also 
known as “hard clustering”. With model-based clustering, sometimes referred to as “soft” or “fuzzy” 
clustering, objects do not have this restriction. An object can belong to several clusters with differing 
probabilities of cluster membership. This mainly affects objects near the edge between two clusters. Hard 
clustering would require them to be placed into one group, whereas model-based clustering means that 
objects can have varying contributions to more than one cluster.2 A priori assumptions on the distribution 
of data provide a framework to facilitate the estimation of cluster membership probabilities.  
The Latent class mixture model (LCMM) is a popular model-based clustering approach that will be used in 
this study. VL measurements will be modelled using mixed effect models with fractional polynomials to 
get a sense of the mean population trajectory. These models allow for differences in individual VL trends 
over time because they utilize a random (growth) slope and intercept that vary across individuals, which 
in turn can yield individual trajectories. The use of fractional polynomials for the models is appropriate 
because they can account for non-linear trajectories and may fit the data better at extreme values 
compared to higher order polynomials.24 The fractional polynomial terms that provide the best fit to the 
mixed effect model will be using in the LCMM to identify distinct classes of individuals VL trajectories. 
Unlike more conventional growth model approaches such as the mixed effects model that assume a single 
estimate of growth parameters can adequately describe the VL growth trajectories of all individuals in the 
data, it allows for different average growth curves to accommodate different classes of individuals.25,26  
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3.5 Number of clusters 
Determining an ideal number of clusters is a major problem yet to be fully addressed in cluster analysis. 
Most nonparametric clustering procedures offer little insight as to the number of clusters that exist in the 
data. Nonparametric approaches for selecting an optimal number of clusters vary. Direct approaches such 
as using the average silhouette27, or maximizing between cluster distance while minimizing within cluster 
distance28 can be attempted. There are also testing procedures with the null hypothesis defined as k = 
1.29,30 Despite the numerous techniques, there is no unanimously accepted method. Like nonparametric 
approaches, the problem of choosing an ideal number of clusters persists when applying model-based 
techniques. Information theory techniques such as Akaike Information Criterion (AIC) and the Bayesian 
Information Criterion (BIC) can be used to determine cluster numbers by selecting models with lowest 
loss of information.  
For this research, the number of clusters will be selected based on domain knowledge and computational 
feasibility. For model-based clustering approach, the optimal number of clusters will be determined using 
both the AIC and BIC of the models and domain knowledge on the types of trajectories expected in the 
data set.  
3.6 Determining cluster membership 
Descriptive statistics of all variables that will be included in the clustering process shall be reported using 
proportions, means with standard deviations and medians with interquartile ranges as appropriate. The 
cluster sizes - i.e. the proportion of the data that each cluster accounts for - will be presented. Clustering 
results will be described graphically by plotting the mean trajectory for each cluster identified for each 
clustering approach used.  
After performing the cluster analysis and detecting the latent longitudinal VL trajectory sub-populations, 
the next step will be to identify which risk factors associated with cluster membership. Descriptive 
statistics will be stratified by clusters obtained to determine which variables may influence cluster 
membership for individuals. The dataset is limited with regard to the variables available for analysis, hence 
there will be few variables used. The variables that will be used for analysis include: 
• Age (in years) 
• Gender 
• Facility type  
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• HIV viral load 
• Time in months since first VL was measured 
4. Potential limitations 
There are many ways to cluster data. Although the body of literature for clustering longitudinal data is 
relatively smaller compared to other forms of multivariate data, it is still substantial. As a result, the 
clustering methods identified are unlikely to be exhaustive. Additionally, the use of routine data means 
that the standards with which they are collected are usually not as high as data for research specific 
purposes which may compromises data accuracy. This also makes it difficult to improve data quality. The 
data obtained may be incomplete for various reasons. For example, there is the possibility of high mobility 
of individuals between services across geographical regions – i.e. moving to other provinces may influence 
results obtained.  
5. Ethical considerations 
All the necessary ethical considerations for undertaking this study have been accounted for. There is no 
conflict of interest to report. There are no incentives to be received and no proprietary interests involving 
any agent, device or software being evaluated by conducting this research. 
5.1 Consent 
This is an analysis of routinely collected retrospective secondary data and individual consent for use was 
not sought. The objectives of the study related to the identification of areas in the public sector 
provision of ART services that could be strengthened, improving care for all individuals living with HIV.  
5.2 Risks 
There are no direct risks to participants as this is an analysis of secondary data and no participants will be 
recruited or enrolled. There is a small indirect risk relating to the potential for loss of privacy and 
anonymity. This risk will be mitigated by ensuring that no personal data will be made available to the 
researchers. Individual names, ID numbers and other identifying information will be removed by the 
parent study data team. Individuals will be identified by a unique, study specific, random identifier. These 
identifiers cannot be linked to a participant’s name or original identity.  




There are no direct benefits to participants contributing data as this is an analysis of secondary data and 
no participants are recruited or enrolled. There may be indirect benefits to people living with HIV as results 
from this research may inform policy on better management of people living with HIV and attending public 
sector services in the Western Cape.  
6. Budget 
This study constitutes the research component of the Master of Public Health (MPH) degree and therefore 
a budget is not necessary. 
7. Timetable  
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8. Stakeholders and dissemination 
The findings from this research may prove important for current efforts towards increased VL suppression 
rates in South Africa. Stakeholders who may be interested in the outcome of the research include 
researchers and clinicians in the field of HIV, relevant policy makers such as the South African National 
Department of Health , the Western Cape provincial health authority, and individuals who have initiated 
or about to initiate ART. Results from this research will be made available through publication in a peer-
reviewed journal and/or by presentation of the findings at local or international conferences. 
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B. LITERATURE REVIEW 
  




South Africa is a middle-income country in Southern Africa that has the largest burden of human 
immunodeficiency virus (HIV) globally.31 It is estimated that there are more than 7 million persons living 
with HIV (PLHIV) in the country.32 As of 2017, the estimated HIV prevalence amongst all South Africans 
was 14%.10 Between 1997 and 2010, it is estimated that more than 2.8 million people lost their lives to 
the disease – a figure higher than any other country in Sub-Saharan Africa.33 There are several 
interventions in place to decrease the number of new HIV infections annually. These interventions include 
voluntary medical male circumcision, promotion of condom use, increased HIV education and awareness 
campaigns.34 The most widespread and effective method for prevention of HIV is  enrollment on 
antiretroviral therapy (ART) for PLHIV.17,35,36 
1.1 The success of ART in South Africa 
The use of ART has transformed the lives of PLHIV and contributed to reducing HIV incidence in the 
country.15 Since the rapid scale up of the South African national ART program, started in 2004, there has 
been a great improvement in life expectancy over the years.15 In 2018, the overall life expectancy for men 
and women had increased to 61.1 years and 67.3 years respectively.37 The scale up has been so extensive 
that South Africa accounts for 20% of all PLHIV on ART globally, making it the largest HIV treatment 
program in the world.38 The South African national ART program has had a tremendous impact on HIV 
prevention efforts. The proportion of new HIV infections has decreased by 40% from 2010-2018.39 There 
has been progress in HIV-related mortality with a decrease from an estimated 200,000 in 2004 to 71,000 
in 2018.32  South Africa still contributes the largest of proportion of all HIV-related deaths at 29% in 
Southern Africa, which when given the size of its HIV burden, is in line with expectations; however, HIV 
incidence remains unacceptably high.39  
In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) launched an ambitious plan targeted 
at the elimination of new HIV infections globally by 2020 (known as 90-90-90 targets).16 This plan requires 
that 90% of all infected persons know their HIV status, 90% of those that know their status to be on 
treatment, and 90% of those on treatment to be virally suppressed. Success in achieving these targets 
would lead to at least 73% of PLHIV achieving viral suppression worldwide. However, for this to 
successfully occur, every country worldwide would have needed to achieve 73% viral suppression of 
PLHIV. 
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1.2 South Africa’s progress towards UNAIDS 2020 targets 
Currently, South Africa has failed to achieve 90-90-90 targets and is unlikely to do so before the target 
deadlines in 2020; having met the first 90% target, it has fallen short on the remaining two.17 As a result, 
it is estimated that only between 38-54% of PLHIV have achieved viral suppression, well behind desired 
2020 targets.17,39 In Southern Africa, South Africa’s neighboring countries have shown that these targets 
are achievable.39 Eswatini, Namibia and Botswana have reached all three 90% targets while Rwanda has 
achieved the first two and is close to achieving the third, however, the magnitude and history of the 
epidemic varies by country.39 South Africa’s failure to meet the 90-90-90 targets while having similar 
resources available may be a reflection of the difference in magnitude of epidemics or in the health system 
response between these countries.  
Achieving a 73% population viral suppression rate nationally is highly dependent on the strength of ART 
adherence – which is a potent predictor of the success HIV treatment programs.40 There are numerous 
factors that influence ART adherence amongst PLHIV; and ability to adhere to lifelong ART often varies on 
an individual, social and demographic level. Individual level factors include adherence self-efficacy, 
current substance abuse, concerns/doubts about ART and trust in an HIV care provider.41 Social factors 
play as big a role in treatment adherence as individual factors. Strong social support has been linked with 
improved adherence whilst high levels of social stigma have been shown to be detrimental.41,42 
Demographic factors such as age and female gender have been associated with a positive impact on ART 
adherence.43  
1.3 Objectives  
Understanding longitudinal patterns of viral suppression among PLHIV on ART may support targeted 
programs to help the health system achieve 90-90-90 targets. To inform this research, the objectives of 
this literature review are as follows: 
• To provide an overview of VL monitoring in South Africa 
• To explore the use of cluster analysis and its applications to longitudinal health data 
• To briefly describe methods to cluster longitudinal health data 
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2. Summary of literature 
2.1 Viral load monitoring in South Africa 
Routine VL monitoring is considered the gold standard in HIV treatment monitoring.18 According to the 
World Health Organization (WHO) guidelines, it is recommended that VL monitoring should be used as 
the primary method for treatment failure or success confirmation for PLHIV enrolled on ART.44 It is the 
most accurate measure of ART’s effect on an individual’s viral suppression. Routine monitoring may have  
the potential to improve the quality of treatment and health outcomes for PLHIV by reducing the time 
spent on a first-line ART regimen that may be failing and aid in identifying cases of poor adherence.45 
In South Africa, routine VL monitoring is used preferentially to CD4 cell count monitoring as a gauge for 
program performance.46 A reason for this is because VL monitoring has been shown to be better at 
predicting mortality of PLHIV on ART.47 All public sector VL testing services fall under the jurisdiction of 
the National Health Laboratory Services (NHLS); the largest diagnostic pathology service in the country 
with availability in every province and an estimated 80% population coverage.19 There were initial 
challenges in implementing VL monitoring as there was a higher level of skill required to conduct testing 
and a significant lack of skilled labor available, commercial assays were costly and cold chain required for 
sample transportation was not always readily available.48 Despite these initial challenges, the volume of 
VL testing services has grown tremendously from 1,625,236 viral assays in 2008 (January to September) 
to 4,949,891 between  2017-2018.48,49 This growth is further expected to rise to meet UNAIDS 2020 
targets.50 
South African national guidelines recommend that routine VL testing should be carried out 6 months after 
patients initiate ART and every 12 months for those who remain virally suppressed.44,46 The definition of 
viral suppression has varied in different settings but is defined as <400 copies/mL according to South 
African national guidelines.46 UNAIDS and the WHO do not explicitly define a VL suppression threshold 
but it is recommended that <1000 copies/mL should be used as there are well described clinical benefits 
for individuals that can maintain VL <1000 copies/mL.44,51 A stricter and less used definition of viral 
suppression is <50 copies/mL which may also be referred to as below the detectable limit (BDL), and is 
largely regarded as the threshold below which transmission will not occur.44,46 
In  South Africa, there are several steps in the process leading up to a VL being “done”.52 Firstly, a blood 
sample is taken from an HIV infected individual who is aware of their status by a health care provider. The 
blood sample is then transported to and processed at a NHLS facility.53 Results of the blood sample are 
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then conveyed back to the health care provider electronically or by delivery. The health care provider then 
explains the results of the VL test to the individual and suggests options for follow up.53 In cases where 
results do not come back with a suppressed VL and regular ART uptake is assumed to be an underlying 
reason for this, enhanced adherence counselling (EAC) is provided and a follow up VL measurement is 
taken.53 First-line ART resistance is assumed where subsequent VL results remain unsuppressed and a 
switch to second-line ART is initiated.46  
Individuals undergoing routine VL monitoring will typically have several repeat measurements of their 
VL over time. This leads to longitudinal VL trajectories which may vary according to pattern and level 
between individuals in the monitoring program.  
2.2 Cluster analysis 
Routine VL monitoring program generates multivariate longitudinal data – which may be defined as repeat 
measurements of one or more variables over time within a group or population of individuals. This data 
is often heterogenous in nature with underlying correlation structures. Cluster analysis is an increasingly 
used data exploration tool used for finding groups in large multivariate longitudinal datasets. It has 
applications in different fields of research including marketing, computer science and machine learning 
theory.2 Despite having various applications in different fields, the underlying principal is the same; 
grouping together objects that are similar and keeping these groups of objects distinct from each other.3  
The significance of cluster analysis has been on the rise in recent times – in part, because of the rise of big 
data and the need for practical and efficient instruments to explore and reveal vital information concealed 
within it.54 Clustering of big data has become more  frequent as powerful computers capable of handling 
growingly complex algorithms needed for analysis are more widely available than ever.3 There has been 
a push towards increasing the volume of repository data kept in patient registries and electronic health 
records (EHR) databases in both developed and developing countries.55,56 Schulam et al.57 note the exciting 
opportunities this affords us for identifying disease subgroups in an objective manner. These large 
datasets containing patient level data with repeated measurements are often complex and have a 
substantial amount of diverse information within them. This diversity may be found in – but is not limited 
to – patient attributes, severity of illness or symptoms, and treatment responses.4 Using cluster analysis 
to gain a deeper understanding of large, longitudinal multidimensional datasets has a few advantages. 
Firstly, it allows for the identification of clinically relevant patient groups with key attributes that could 
lead to more tailored and enhanced care.4 Additionally, in situations where the diagnostic criteria for 
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certain mental and physical illnesses are either too limited or too vague, cluster analysis can provide 
clearer and more valid criteria to aid health professionals.4 
2.3 Cluster analysis and Longitudinal studies  
Longitudinal studies are an important, intrinsic feature in epidemiological research.2 They allow 
researchers to observe changes in the outcome of interest in individuals, families or populations over time 
and allow us to gain important insights in growth, development, and life span related health topics.58 A 
key advantage of longitudinal studies is their ability to relate outcomes to specific exposures in a more 
flexible way than cross-sectional studies  because of their temporal nature.58 Longitudinal data require 
non-conventional, specific clustering techniques.2 This is because longitudinal data is often sparsely and 
irregularly measured and commonly has a significant amount of missing data.2 Furthermore, objects are 
rarely independent from each other due to the time ordering of their measurements.2 
2.3.1 Argument for cluster analysis for VL monitoring 
A systematic review by Pinaire et al.59 highlighted the growing  interest in the study of individuals’ 
longitudinal health trajectories using health indicators like VL as monitoring tools. The review noted that 
despite the increase in these types of studies in recent years, cluster analysis is not a method commonly 
used for their analysis.59 This finding may be extended to South Africa, which has little literature regarding 
clustering of health related trajectories. The large volume of longitudinal data from South Africa’s routine 
VL monitoring program requires objective analytic approaches such as cluster analysis to account for the 
heterogeneity that may be found within it. Conventional analyses performed on the data are often limited 
to the overall population suppression rates – commonly stratified by arbitrary categories such as age 
groups, sex and province.12,17 This approach yields important information on program performance but 
has its limitations. Firstly, the repeated use of subjective categories based on previous literature hinders 
the discovery of other clinically relevant population subgroups. De Keulenaer et al.60 argue for the use of 
more objective, data-driven methods for identifying potentially important population subgroups when 
studying chronic diseases such as heart failure. Another drawback is that these analyses frequently focus 
solely on viral suppression as a proportion of PLHIV and ignore the pattern of individuals’ viral load 
trajectories – which may help us understand disease progression. Genolini et al.23 posit that the clustering 
individuals’ trajectories according to shape could help reveal important insights that classical analyses 
cannot.  
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A better comprehension of trajectories permits us to anticipate the people that have the greatest risk for 
adverse trajectories and outcomes, better understand factors that influence variation in health over time,  
grant the ability to investigate effects of interventions on the trajectories – including identifying for whom 
and at what point in the trajectory interventions may be most effective.61  
2.3.2 Applications of longitudinal data clustering in general health research 
There are many applications of longitudinal data clustering in health research that cover a vast and diverse 
range of research fields such as clinical trials20, genetics62, and physiology63. A few examples will be 
provided to demonstrate the flexibility of cluster analysis in varying health research fields.  
Pate et al.64 identify three distinct physical activity trajectories amongst youth progressing from grade five 
through to grade eleven. Of the trajectories they discovered, there was one that had youth’s physical 
activity decreasing to very low levels as they aged from 10-16 years of age.64 Gender and their  fifth grade 
body mass index were factors associated with this group.64 Shoji et al.65 presented a novel approach to 
clustering hospital laboratory examinations. They showed that their approach could be used to analyse 
relationships between platelet count and albumin trajectories and how they influence fibrotic stages.65 
Their findings showed varying distribution of fibrotic stages in discovered clusters suggesting an 
underlying influence between the trajectories and fibrotic stages.65  
Jensen et al.66 carried out a massive, population wide, disease trajectory clustering using the Danish 
national patient registry that consisted of 6.2 million patients. They transformed this vast amount of data 
– which used the entire range of diseases found in 14.9 years worth of registry data -  into 1,171 disease 
trajectories. Although their research was focused more on grouping of disease trajectories rather than 
patient trajectories, they were nevertheless able to show that this approach can reveal diagnosis linkages  
that may have previously had uncertain or contradictory associations through conventional 
epidemiological studies.66 
2.3.3 Applications of longitudinal data clustering in HIV research 
Cluster analysis has previously been applied to HIV research in South Africa. Gosset et al.67 investigated 
retention in care (RIC) trajectories for 777 individuals eligible for ART using group-based cluster analysis 
in rural South Africa. They found four clustered trajectories:  A “remained in care” cluster that accounted 
for 71.3% of the patients, an “exited care then returned” cluster that accounted for 5.2% of patients, an 
“exited care rapidly” cluster that accounted for 12.6% of patients, and finally, an “exited care later” that 
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accounted for 10.9% of patients.67 They concluded that in order to maximize RIC,  swift ART initiation and 
focused support for young and newly diagnosed PLHIV is necessary.67 
Likewise, cluster analysis has been used for understanding VL suppression trajectories. Kassaye et al.68 
used  a cohort study of 1989 HIV infected women in the United States to find three distinct trajectory 
groups representing varying probability of viremia. The groups were categorized as low probability (28.6% 
of participants), intermediate probability (39.4% of participants) and high probability (32% of 
participants).68 Factors such as drug use, depression symptoms and younger age were associated with the 
high probability group which highlighted the need to focus efforts towards mental health and other 
behavioral factors that are associated with a higher viremia probability.68 
2.4 Clustering methods for longitudinal data 
There are numerous ways to cluster trajectories, but they can be broadly categorized into two methods; 
parametric and non-parametric clustering.2,20 The key difference between the two methods is that non-
parametric clustering makes few assumptions of the distribution of the data, instead focusing on explicitly 
defining similarity.2 
2.4.1 Nonparametric clustering 
The most important components of this approach involve the choice of measure for distinctiveness 
between individuals, the clustering algorithm and the number of clusters in the data. This clustering 
technique is often described as “hard clustering” because an object can belong to only one cluster.2  
Measures of distinctiveness 
There are several terms used for a measure to quantify the distinctiveness between two individuals. These 
terms are sometimes called a metric, distance function, dissimilarity function or similarity function. 
Although closely related to each other, these terms do not necessarily measure distinctiveness the same 
way. For example, all metrics can be said to be distance functions, but the reverse is not always the case.2 
The choice of distance measure is crucial and can often have a large impact on clustering results, 
therefore, it must be carefully considered before being used.2 
Clustering algorithm 
These are generally classified as Hierarchical and partitioning algorithms.3 Partitioning algorithms cluster 
the data into two or more groups. These groups must jointly satisfy the following conditions of a partition: 
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• At least one object must be in each group 
• An object cannot belong to more than one group 
A “good” partition is one where the objects in a group are very similar, while objects in different clusters 
are very different.2,3  
Hierarchical algorithms work differently from partitioning algorithms. Rather than partition the data into 
k clusters at an instance, they handle all values of k in a single run.3 This means that a partition with a 
single cluster (k = 1) and a partition with each object forming a separate cluster (k = n) are presented 
together, with all values of k = 2, 3, . . . , n-1 shown in between as a gradual transition. This method can 
either be agglomerative (starting from n clusters and gradually combining them into one cluster) or 
divisive (starting from one cluster and gradually dividing them into n clusters). Hierarchical algorithms 
often require a priori knowledge on the number of clusters to be selected.2 
Number of clusters 
Determining the optimal number of clusters in a dataset has historically been a challenge.2 There is no 
gold standard in approach for selecting an optimal number of clusters. Non testing procedures such as 
minimizing the within cluster dissimilarity while maximizing the between cluster dissimilarity28 or using 
the average silhouette27 are available options. More formal testing approaches are also available that use 
a null hypothesis that not more than one cluster exists in the dataset.29,30  
2.4.2 Model-based clustering  
Unlike nonparametric approaches, which require each object to explicitly belong to only one cluster, 
model-based clustering and related methods allows objects may belong to several clusters with varying 
probability of membership. This is known as fuzzy or soft clustering and allows for uncertainty in the data.3 
This is useful for objects between the boundary of two clusters. Assumptions on the data distribution are 
made a priori and have an advantage of providing more comprehensive information on the data 
structure.3 The most used model for clustering longitudinal data is the finite mixture model.20  
Just as with nonparametric approaches, determining the optimal number of clusters poses a challenge for 
researchers.2 A common approach to selecting a model that uses the ideal number of clusters is the use 
of information theory methods. Akaike information criterion (AIC) and Bayesian information criterion 
(BIC) are two of the most popular information criterions used for this. Models are compared based on 
these criterion and the model with the smallest loss of information is chosen.2  




The size of South Africa’s VL monitoring program has had a tremendous growth in capacity in recent years 
despite initial struggles in its launch. The program is crucial to measuring the programmatic success of 
ART in the country. Cluster analysis may be an approach to uncover latent trajectories of individuals’ VL 
patterns that may help in the development of targeted HIV prevention programs. This is especially true 
for large multidimensional datasets like that from NHLS data on routine VL monitoring. Cluster analysis 
has been demonstrated to have several advantages beyond conventional, subjective analysis of 
longitudinal data.  
4. Areas for further research 
The review has brought focus to the considerable body of evidence for cluster analysis in health research. 
Despite being applicable to numerous scenarios and settings, there are few studies that use cluster 
analysis in for HIV research in South Africa. There is an application for further HIV-related studies that use 
cluster analysis – not limited to analyzing trajectories – that may help identify HIV disease and patient 
subgroups that may have clinical relevance, if any exist. This information may help define better treatment 
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Introduction: Data from routine viral load monitoring is important for assessing the programmatic 
effectiveness of antiretroviral treatment (ART) in South Africa, but this is usually analysed in a cross-
sectional manner and there are few analyses of longitudinal viral load trajectories over time. Cluster 
analysis was used to identify latent viral load trajectory patterns in a large dataset of routinely collected 
viral load measurements in the Western Cape, South Africa. 
Methods: We analysed available VL measurements collected during routine care from the Western Cape 
public sector antiretroviral treatment programs, including all people living with HIV who were enrolled on 
ART and had experienced at least one elevated (>1000 copies/mL) viral load test result between 2008 and 
2018. Empirical rules-based classification, nonparametric clustering using the KML-Shape algorithm and 
model-based clustering using latent class mixture modelling were used to cluster viral load trajectories. 
Results: Both the nonparametric and model-based clustering techniques identified five latent viral load 
trajectory subgroups. The shapes and magnitudes of these subgroups differed according to method. 
Majority of individuals’ trajectories belonged to clusters that had a decreasing VL trend. Most of the 
trajectory subgroups identified had prolonged periods of low-level viremia. Both methods identified viral 
load trajectory clusters that increased over time. 
Conclusion: Cluster analysis is a useful tool for identifying latent VL trajectory clusters in the Western Cape 
and the dynamic VL cluster patterns that exist among the large VL dataset can offer important insights. 
Further research is needed to understand factors associated with belonging to these clusters to improve 













South Africa has the largest ART program in the world.12 The program has played a significant role in 
reducing HIV related mortality and improving HIV prevention efforts in the country.13,14 It is estimated that 
over 6 million adult life years have been saved and the cumulative number of HIV related deaths in adults 
was lessened by 1.72 million because of the national ART program.69 Routine viral load (VL) monitoring is 
important for evaluating the ART program effectiveness over times. Routine viral load (VL) monitoring is 
the World Health Organization (WHO) recommended strategy for measuring treatment response and 
identifying treatment failure among people living with HIV (PLHIV)5,6. Routinely collected data from 
treatment programs can be used to understand population viral suppression rates cross sectionally as well 
as longitudinally and to identifying groups of individuals who may have difficulty with ART adherence or 
be experiencing treatment failure.18  
The conventional approach to analysing routine VL data is often focused on cross sectional viral 
suppression rates.50,53,70,71 While cross-sectional approaches yield important information, they ignore 
individuals’ longitudinal VL trajectory or patterns of viremia. Most work evaluating viral suppression has 
also used pre-specified population subgroups based on existing literature such as sex, race, geographic 
location, or age group. There has been a substantial increase in the volume of the country’s VL testing 
services; reaching approximately 5 million viral load tests in 2017/18.49 This increase in volume provides 
an exciting opportunity to use data-driven approaches to identify latent subgroups of VL trajectories, 
clusters not defined using a-priori categories. Cluster analysis is used in many disciplines including 
marketing, politics and economics and can be  a powerful data exploration tool for finding unobserved 
patterns in multivariate data.3  
There is a dearth of research on how longitudinal VL patterns for individuals who experience at least one 
elevated VL (defined as > 1000 copies/mL) change over time in South Africa. It is likely that there are 
several latent subgroups of VL trajectories for this population and an improved understanding of different 
patterns and frequency of pattern occurrence may be useful in targeting support programs.  Discovering 
these subgroups of VL trajectories may help identify characteristics of individuals in care who are more 
likely to develop VL trajectories associated with negative outcomes before they occur and may provide 
deeper a deeper understanding of the underlying mechanism for their trajectories. This study aims to 
bridge the knowledge gap between routine VL monitoring and the type of longitudinal VL patterns that 
exist for PLHIV on ART in South Africa. 





We reviewed routinely collected HIV VL measurements from the Western Cape province in South Africa 
collected by the public sector ART program and processed by the National Health Laboratory Service 
(NHLS) over a 10 year period from 2008 to 2018. Data was provided as linked records giving a unique 
longitudinal time series for individuals. We excluded individuals from all analyses that either had less than 
two VL measurements or only had VL results of <1000 copies/mL throughout the 10 year observation 
period. There was minimal clinical and demographic characteristics available from the dataset, including 
age, date of VL test, sex and facility type. 
Individual characteristics were summarized by frequency (percentage) or median (interquartile range) as 
appropriate. We used three thresholds for viral suppression to compare clustering results; the first was 
the World Health Organization (WHO) threshold defined as any VL <1000 copies/mL, the second was the 
South African national guidelines threshold defined as any VL <400 copies/mL, and the third was a very 
conservative threshold of any VL <50 copies/mL. 
2.2 Clustering 
Raw VL measurements (copies/mL) were log10 transformed prior to all analyses. An empirical rules-based 
approach to classification was used to describe the VL trajectories. Individuals were classified into one of 
4 groups, defined by a single elevated (>1000 copies/mL) VL at or not at the first visit, multiple elevated 
VL with at least one VL <1000 copies/mL, and all VL elevated.     
Both model-based and nonparametric approaches to cluster the VL trajectories were applied. A k-means 
approach for longitudinal data based on shape (KML-Shape) was applied to the data, first applying a data 
size reduction technique recommend by Genolini et al.22 to make the algorithm less computationally 
expensive. For the model-based approach we first modelled individuals’ repeated VL measurements using 
a mixed effects model with fractional polynomial terms to account for non-linear VL trajectories. The 
fractional polynomial terms that provide the best fit to the mixed effect model were then used in a latent 
class mixture model to identify distinct clusters of individuals’ VL trajectories. 
We compared the available demographic characteristics of individuals amongst the clusters obtained from 
both clustering methods to identify which factors may influence cluster membership. Longitudinal profiles 
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and mean cluster profiles were plotted for visual inspection and to assist with description of the resulting 
clusters. All analysis was carried out in R (R Foundation, Vienna, Austria). 
The University of Cape Town Human Research Ethics Committee reviewed and approved the research 
protocol.  
 
Table 1. Characteristics of individuals used for clustering. 
 
Variables Value 
Number of individuals (N) 109092 
Number of tests (N) 680751 
Number of tests per person [median (IQR)] 5 (3, 9) 
Duration between tests (months) [median (IQR)] 7.2 (5.1, 10.7) 
Number of virally suppressed tests [N (%)]  
   < 1000 copies/mL 397889 (58.4) 
   < 400 copies/mL 364399 (53.5) 
   < 50 copies/mL 282278 (41.5) 
First test results [N (%)]  
   < 1000 copies/mL 50580 (46.4) 
   < 400 copies/mL 46909 (43) 
   < 50 copies/mL 36985 (33.9) 
Number of individuals always elevated [N (%)]  
   > 1000 copies/mL 14297 (13.1) 
   > 400 copies/mL 17277 (15.8) 
   > 50 copies/mL 28944 (26.5) 
Age in years [median (IQR)] 32 (26‐38) 
Sex [N (%)]  
   Female 71080 (65.2) 
   Male 38012 (34.8) 
Facility type [N (%)]  
   Clinic 53055 (48.6) 
   Hospital 53928 (49.4) 
   Military 155 (0.1) 
   Prison 1954 (1.8) 
VL categories [N (%)]  
   Single elevated VL at first visit 22556 (20.7) 
   Single elevated VL not at first visit 24234 (22.2) 
   Multiple elevated VL with at least one suppressed VL 48005 (44) 
   Elevated throughout 14297 (13.1) 




3.1 Background characteristics of patients 
Of the 469,161 individuals in the NHLS dataset, we removed 122,313 (26%) that had only one VL 
measurement, we then removed 237,561 (50.7%) that did not have at least one elevated VL (≥ 1000 
copies/mL). A total of109,092 (23.3%) individuals and 680,751 VL tests remained eligible for analysis. The 
demographic characteristics of the individuals are displayed in Table 1. The majority of individuals were 
female (65.2%) and the median (IQR) age in years for participants was 32 (26-38). The median (IQR) 
number of months between tests for individuals was 7.2 (5.1-10.7). Most VL tests were performed at 
either a clinic (48.6%) or a hospital (49.4%). The proportion of VL test results that were virally suppressed 
at first visit was less than half using <1000 copies/mL threshold (46.4%), <400 copies/mL (43.0%) and <50 
copies/mL (33.9%) 
Figure 1. A sample of 500 individual VL trajectories with a loess smoother (blue line) illustrating pattern of change over time 
categorized into 4 groups. A) Single elevated not at first visit: Individuals with a single elevated VL that does not occur on their 
first visit. B) Multiple elevated: Individuals who have multiple elevated VLs with at least one suppressed VL. C) Single elevated at 
first: individuals who have a single elevated VL only at their first visit. D) Elevated throughout: Individuals who never have a 
suppressed VL  
Because all participants had at least one elevated VL in the analysis set, we classified individuals based on 
the number and timing of their elevated VL test results into four categories. The largest single group of 
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individuals had multiple elevated VL with at least one VL < 1000 copies/mL (44%), 22% had a single 
elevated VL not occurring at the first visit, 21% a single elevated viral load occurring at the first visit and 
the remaining 13% had elevated VL (>1000 copies/mL) throughout (Table 1). A sample of 500 VL 
trajectories selected randomly from these groups is plotted with a loess smoother superimposed to show 
the nature of the longitudinal VL patterns (Figure 1). 
3.2 Clusters identified 
The KML-Shape approach yielded five VL trajectory clusters that varied in pattern and direction (Figure 2). 
Three clusters contained the majority of individuals and are described as “Elevated with steady decrease” 
(41%), “Steady low-level viremia (<1000 copies/mL)” (30%) and “Elevated with steady increase” (23%). 
The remaining two clusters contained a much smaller proportion of individuals and are described as 
“Elevated with rapid decrease” (5%) and “Elevated throughout” (<1%).  Individuals in the “Elevated 
throughout” cluster did not have records longer than 72 months, which may be an indicator of late entry 
to the data set or loss to follow up from the VL monitoring program. 
Figure 2. Five VL trajectory clusters identified using the nonparametric approach KML-Shape. A) Initially elevated, then steady 
decline VL trajectory cluster. B) < 1000 copies/mL throughout. C) Initially elevated, then steady increase VL trajectory cluster. D) 
Initially elevated, then rapid decline. E) Very high elevated VL. Trajectories are plotted by averaging over a bin of 25 time points. 
The proportion of individuals classified to each cluster is indicated at the top right. 
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This observation was similar to the sample VL trajectories identified through the rules-based approach as 
“elevated throughout” and shown in Figure 1D that have shorter than average follow up periods (<60 
months). 
Figure 3. Five VL trajectory clusters identified using model-based approach LCMM with fractional polynomials. Proportion of 
individuals are displayed in the top right of each cluster. A) Initially elevated, then steady decline. B) Initially elevated, then rapid 
decline. C) Elevated blip. D) Undetected, then low-level viremia. E) Rapid elevation. Trajectories are plotted by averaging over a 
bin of 25 time points. The proportion of individuals classified to each cluster is indicated at the top right. 
The LCMM approach also identified five VL trajectory clusters which generally differed in shape compared 
to those of the KML-Shape approach (Figure 3). Somewhat unlike the KML-Shape approach, individuals 
were more broadly dispersed, with four clusters containing 19% or more of the individuals. These four 
main clusters can be described as “Elevated with steady decrease” (22%), “Elevated with rapid decrease” 
(31%), “Viral blip” (19%), “Low-level viremia” (24%). The fifth cluster, containing only 5% of individuals 
can be described as one of “Rapid increase”.  The mean VL trajectories resulting from this approach were 
more dynamic in shape compared to the KLM-Shape approach and although have been described using 
similar terms, the range of VL values covered by each cluster also differed (Figure 2 and Figure 3). The 
mean LCMM VL trajectories captured more rapid change, which can be observed by the relatively steeper 
slopes when compared to those of KML-Shape. 
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Table 2. A comparison of cluster types between both KML-Shape and LCMM to Empirical clusters in the dataset 
 Empirical KML-Shape LCMM 
Type of cluster obtained*    
Elevated with rapid decrease 22556 (20.7) 5513 (5.1) 33318 (30.5) 
Elevated with steady decrease  44785 (41.1) 23851 (21.9) 
Viral Blip 48005 (44)  20878 (19.1) 
Low‐level viremia 24234 (22.2) 33203 (30.4) 25737 (23.6) 
Suppressed then sharp increase   5308 (4.9) 
Elevated with steady increase  24869 (22.8)  
Elevated VL throughout 14297 (13.1) 722 (0.7)  
*Blanks indicate that the cluster type was not found under the method. 
 
Table 3. Characteristics of individuals stratified by cluster types obtained from KML-Shape 












Number [N (%)] 44785 (41.1) 33203 (30.4) 24869 (22.8) 5513 (5.1) 722 (0.7) 
Gender [N (%)]      
   Female 29557 (66) 21890 (65.9) 15807 (63.6) 3400 (61.7) 426 (59) 
   Male 15228 (34) 11313 (34.1) 9062 (36.4) 2113 (38.3) 296 (41) 
Facility Type [N (%)]      
   Clinic 22095 (49.3) 15570 (46.9) 12512 (50.3) 2513 (45.6) 365 (50.6) 
   Hospital 21731 (48.5) 17125 (51.6) 11902 (47.9) 2824 (51.2) 346 (47.9) 
   Military 74 (0.2) 39 (0.1) 32 (0.1) 10 (0.2) N/A 
   Prison 885 (2) 469 (1.4) 423 (1.7) 166 (3) 11 (1.5) 
Age [median (IQR)] 31 (26‐38) 32 (25‐38) 31 (26‐38) 32 (26‐39) 32 (26‐40) 
Duration between tests (months) [median 
(IQR)] 6.1 (3.8‐10.8) 6.3 (4.3‐9.5) 6.7 (4.2‐12.2) 6.5 (4.4‐9.1) 5.2 (2.9‐9.7) 
Number of tests [median (IQR)] 5 (3‐8) 7 (4‐10) 4 (3‐7) 5 (3‐7) 2 (2‐3) 
Number of individuals suppressed at first 
test [N (%)]      
   VL < 1000 18095 (40.4) 18050 (54.4) 13264 (53.3) 1103 (20) 68 (9.4) 
   VL < 400 16461 (36.8) 17018 (51.3) 12358 (49.7) 1012 (18.4) 60 (8.3) 
   VL < 50 12334 (27.5) 14264 (43) 9590 (38.6) 765 (13.9) 32 (4.4) 
Number of individuals always 
elevated [N (%)]      
   VL always > 1000 5415 (12.1) 425 (1.3) 7473 (30) 1 (0) 608 (84.2) 
   VL always > 400 6490 (14.5) 1630 (4.9) 8469 (34.1) 19 (0.3) 619 (85.7) 
   VL always >50 11288 (25.2) 5724 (17.2) 11131 (44.8) 152 (2.8) 649 (89.9) 
VL categories [N (%)]      
   Single elevated VL at first visit 11763 (26.3) 7285 (21.9) 101 (0.4) 3407 (61.8) N/A 
   Single elevated VL not at first visit 9261 (20.7) 8722 (26.3) 5598 (22.5) 609 (11) 44 (6.1) 
   Multiple elevated VL with at least one 
suppressed VL 18201 (40.6)  16754 (50.5)  11521 (46.3)  1496 (27.1)  33 (4.6)  
   Elevated throughout 5560 (12.4) 442 (1.3) 7649 (30.8) 1 (0) 645 (89.3) 
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Table 2 compares the methods of classification using the descriptive terminology along with the number 
(percent) of individuals classified into each group. By inspection, only the “Elevated with rapid decrease” 
VL cluster type was present under all three approaches, aligning very much to a first elevated VL followed 
by viral suppression. However, the sizes of these clusters varied with KML-Shape being the smallest. KML-
Shape identified more cluster types (3 in total) that were expected a priori compared to LCMM (2 in total); 
however, the difference in proportion of individuals in each cluster type for all three varied greatly 
suggesting possible misclassifications of VL trajectory clusters.  
Table 4. Characteristics of individuals stratified by cluster type obtained from LCMM 












Number of individuals [N (%)] 23851 (21.9) 33318 (30.5) 20878 (19.1) 25737 (23.6) 5308 (4.9) 
Gender [N (%)]      
   Female 14515 (60.9) 22081 (66.3) 13992 (67) 17344 (67.4) 3148 (59.3) 
   Male 9336 (39.1) 11237 (33.7) 6886 (33) 8393 (32.6) 2160 (40.7) 
Facility type [N (%)]      
   Clinic 12082 (50.7) 15635 (46.9) 10620 (50.9) 11997 (46.6) 2721 (51.3) 
   Hospital 11145 (46.7) 16591 (49.8) 10060 (48.2) 13596 (52.8) 2536 (47.8) 
   Military 55 (0.2) 85 (0.3) 2 (0) 11 (0) 2 (0) 
   Prison 569 (2.4) 1007 (3) 196 (0.9) 133 (0.5) 49 (0.9) 
Age in years [median (IQR)] 31 (25‐38) 31 (25‐38) 32 (26‐38) 32 (26‐39) 32 (27‐39) 
Duration between tests (months) 
[median (IQR)] 5.5 (3.3‐10.5) 5 (3.4‐8.3) 7.5 (5.5‐12) 6.9 (5.5‐10) 9.2 (5.9‐19.4) 
Number of tests [median (IQR)] 4 (2‐7) 4 (3‐7) 6 (3‐10) 7 (5‐11) 5 (3‐8) 
Number of first test results [N (%)]      
   VL < 1000 copies/mL 588 (2.5) 579 (1.7) 19339 (92.6) 25350 (98.5) 4724 (89) 
   VL < 400 copies/mL 146 (0.6) 283 (0.8) 17439 (83.5) 24798 (96.4) 4243 (79.9) 
   VL < 50 copies/mL 14 (0.1) 182 (0.5) 12611 (60.4) 21553 (83.7) 2625 (49.5) 
Number of individuals always elevated 
[N (%)]      
   VL always >1000 copies/mL 13217 (55.4) 668 (2) 186 (0.9) 9 (0) 217 (4.1) 
   VL always > 400 copies/mL 14687 (61.6) 1427 (4.3) 906 (4.3) 26 (0.1) 611 (11.5) 
   VL always > 50 copies/mL 17950 (75.3) 5117 (15.4) 3813 (18.3) 436 (1.7) 2251 (42.4) 
VL categories [N (%)]      
   Single elevated VL at first visit 10396 (43.6) 9983 (30) 11565 (55.4) 11940 (46.4) 4121 (77.6) 
   Single elevated VL not at first visit 152 (0.6) 417 (1.3) 8989 (43.1) 13706 (53.3) 970 (18.3) 
   Multiple elevated VL with at least 
one suppressed VL 86 (0.4) 22250 (66.8) 138 (0.7) 82 (0.3) N/A 
   Elevated throughout 13217 (55.4) 668 (3) 186 (0.9) 9 (0) 217 (2.1) 
 
Individuals and test characteristics were compared across the different clusters obtained from both LCMM 
and KML-Shape approaches (Tables 3 & 4). In the LCMM method, median duration between tests in 
months was shorter for the VL trajectory clusters that showed a downward trend compared to those that 
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had a rising trend. The median number of tests was also lower for downward trend clusters compared to 
the other clusters, suggesting that LCMM is in part classifying individuals based on the number of available 
tests. There was a negligible difference in the median duration between tests in months for all clusters in 
the KML-Shape, with the exception of the “Elevated VL throughout” cluster. The “Elevated throughout” 
cluster had a higher proportion of males when compared to other clusters (KML-Shape).  
4. Discussion 
This study identified five latent VL trajectory clusters using a nonparametric and model-based approach 
for individuals in the Western Cape who have had at least one elevated VL. To the best of our knowledge, 
a study of this nature and has not been carried out using routine VL data in South Africa. The findings of 
the study provided a unique insight on the VL trajectory patterns of individuals who have had at least one 
elevated VL over a 10-year period. It builds upon the base of knowledge for VL monitoring and ART 
performance in South Africa. Study findings showed that beyond the trajectories expected to be in the 
data, there are several other latent trajectories that require further investigation. The likelihood of being 
classified in groups with undesirable VL trajectories may be due to factors such as poor adherence or the 
distance to the nearest health care facility; targeted program interventions can be directed towards high 
risk patients to improve their long-term outcomes. The analysis presented also demonstrates the 
importance of method selection, as the three approaches did not align well in terms of classification to 
common clusters.  
Most trajectories identified in this analysis, and the largest proportion of individuals, were assigned to 
clusters that had an overall trend towards viral suppression. This is a positive finding and suggests that 
overall, individuals with elevated viral loads achieve re-suppression. Under all approaches there remained 
a small cluster of individuals with consistently elevated VL results. This observation is concerning as it 
suggests there is a small group of individuals in care who remain viremic. This group differed from other 
clusters only in the average number of tests, and so may reflect a shortcoming of the data rather than a 
clinical issue of concern.   
All VL trajectory clusters identified that showed an initially elevated VL usually declined – either rapidly or 
steadily – towards viral suppression but still had prolonged periods of low-level viremia (LLV). LLV can be 
defined using different thresholds depending on the level of development of the country, but in the case 
of South Africa is generally considered as either between 50 to 400 copies/mL (very low) or 400 to 1000 
copies/mL. LLV is associated with an increased risk of virologic failure, switch to second-line ART and HIV 
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related mortality.72 The finding that there may be reason to consider the rate of viral load change over 
time is an important one that should be further investigated.  
This study has several strengths. Firstly, the discovery of these latent VL trajectories was done using 
objective, data-driven approaches. Secondly, the large number of records in the NHLS database covers 
the entirety of the region which greatly reduces the occurrence of selection bias. Furthermore, the high 
rates of public sector care in the Western Cape over a considerable time period means there is good 
population representation of individuals in care.  
 
There are also several limitations to the study. Because the data was collected from routine data, the 
number of covariates, and hence possible risk factors, was limited, meaning further investigation to 
ascertain factors associated with membership of clusters of interest was not possible. The time between 
VL measurements are unevenly spaced out. As a result, there may be long periods between 
measurements were the VL may have varied significantly. The lack of data between these periods may be 
considered missing in this context as it would have been useful for clustering. Another limitation was that 
there was little agreement in the level, slope and size of the clusters obtained between the two 
approaches. Although, this outcome was expected because the KML-Shape algorithm focuses more on 
grouping trajectories of similar shapes together rather than trajectories of similar level, it leads to 
difficulty in interpretation of the resulting clusters. The demonstrated difference in cluster size between 
the two approaches and what was shown empirically is noteworthy but also understandable within the 
context of the clustering approaches not using explicit elevated VL thresholds.  
5. Conclusion 
Data from routine VL monitoring has a greater potential for offering more insights on the patterns of VL 
progression over time. Cluster analysis provided a useful tool for unearthing previously unobserved 
patterns in large heterogenous data like that of NHLS VL data. Further research is needed to understand 
how these patterns affect population suppression rates which may be able to contribute to ongoing 
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1. SUBMISSION
Please carefully read through the Instructions for Authors and prepare your manuscript according to 
the guidelines, including structuring it manuscript based on the chosen article category. Manuscripts 
that do not follow the instructions may be returned to the authors for corrections. 
Authors should kindly note that submission implies that the content has not been published or 
submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific 
meeting or symposium. 
Once the submission materials have been prepared in accordance with the Author 
Guidelines, manuscripts should be submitted online 
at https://mc.manuscriptcentral.com/jias. The submission system will prompt authors to use 
an ORCID iD (a unique author identifier) to help distinguish their work from that of other 
researchers. Click here to find out more. 
You will be asked to suggest potential peer reviewers for your manuscript: they should be experts in 
the field and be able to provide an objective assessment of the manuscript. Any suggested peer 
reviewers should not have published with any of the authors of the manuscript within the past five 
years, should not be current collaborators, and should not be members of the same institution. 
Suggested reviewers will be considered alongside potential reviewers identified by the Editorial 
team. 
Click here for more details on how to use ScholarOne. 
2. AIMS AND SCOPE
The JIAS welcomes submissions on HIV-related topics from across all scientific disciplines, including 
but not limited to: 




• Health economics and health policy
• Operations research and implementation sciences
• Social sciences and humanities, including political sciences and media
The JIAS prioritizes submissions from operational research and implementation science as 
publication of such material can provide valuable information on various algorithms for monitoring 
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and providing support for comprehensive, yet affordable and sustainable treatment, prevention and 
care programmes in different contexts. 
 
Submission of HIV research carried out in low- and middle-income countries is strongly encouraged. 
 
3. MANUSCRIPT CATEGORIES AND REQUIREMENTS 
The JIAS accepts submissions in the following categories: 
• Research 




• Letter to the Editor 
• Viewpoint 
 
Research - full reports of data from original research studies 
Abstract: 
Headings: Introduction, Methods, Results, Conclusions 
Word limit: 350 words 
Main text: 
Headings: Introduction, Methods, Results, Discussion, Conclusions 
Word limit: 3500 words 
Numbers of figures and tables: Unlimited 
Additional files: Yes 
Download the manuscript template 
 
Short report - brief reports of data from original research, such as follow-up or confirmatory 
studies, case series and negative results 
Abstract: 
Headings: Introduction, Methods, Results and discussion, Conclusions 
Word limit: 350 words 
 
Main text: 
Headings: Introduction, Methods, Results and discussion, Conclusions 
Word limit: 2000 words 
Numbers of figures and tables: 3 
Additional files: No 
Download the manuscript template 
 
Review - comprehensive, authoritative descriptions and summaries of a specific subject area 
providing a systematic and substantial overview of the field 
Abstract: 
Headings: Introduction, Methods, Results and discussion (if applicable, otherwise Discussion only), 
Conclusions 
Word limit: 350 words 
Main text: 
Headings: Introduction, Methods, Results and discussion (if applicable, otherwise Discussion only), 
Conclusions 
Word limit: 5000 words 
Numbers of figures and tables: Unlimited 
Additional files: Yes 
   
58 
 
Download the manuscript template 
 
Debate - presentation of an evidence-based argument 
Abstract: 
Headings: Introduction, Discussion, Conclusions 
Word limit: 350 words 
 
Main text: 
Headings: Introduction, Discussion, Conclusions 
Word limit: 3500 words 
Numbers of figures and tables: 4 
Additional files: No 
Download the manuscript template 
 
Commentary - focused and opinionated articles on important and timely issues, no original 
data 
Abstract: 
Headings: Introduction, Discussion, Conclusions 
Word limit: 350 words 
 
Main text: 
Headings: Introduction, Discussion, Conclusions 
Word limit: 2500 words 
Numbers of figures and tables: 1 
Additional files: No 
Download the manuscript template 
 






Word limit: 500 words 
Numbers of figures and tables: None 
Additional files: No 
Download the manuscript template 
 






Word limit: 1000 words 
Numbers of figures and tables: 1 
Additional files: No 
Download the manuscript template 
 
4. PREPARING THE SUBMISSION 




In the cover letter, please explain why your manuscript should be published in the journal. If 
necessary, address any issues relating to our editorial policies .and declare any competing interests 
(see Editorial Policies and Ethical Considerations) 
Parts of the Manuscript 
The manuscript should be submitted as a main text file including figures and appendices and 
supporting information should be supplied as separate files. 
Main Text File 
The text file should be presented in the following order: 
1. Title page; 
2. Keywords; 
3. Abstract; 
4. Main text; 







The title should not contain abbreviations, except commonly used abbreviations such as HIV or 
AIDS (see Wiley's best practice SEO tips ). 
On the title page, you should mention the title of the manuscript, list all authors' names in full, and list 
any study groups if applicable. Each authors' affiliation should be numbered in superscript 
consecutively and listed underneath, including department, institution, city and country. 
The corresponding author should be marked with the symbol § in superscript and full contact details 
should be provided, including a telephone number with country code. Authors who have contributed 
equally to the work should be marked with the symbol * in superscript. Deceased authors should be 




Pease provide six keywords. Keywords should be taken from those recommended by the US 
National Library of Medicine's Medical Subject Headings (MeSH) browser list 
at https://www.nlm.nih.gov/mesh/. Preferably alternate words to those found in the abstract in 
order to improve search hits for the article in repositories. 
Abstract 
The Abstract should not exceed 350 words and should be structured according to the headings of 
the selected article category (see above), excluding the heading “Discussion” for Research articles. 
Avoid using abbreviations and do not cite references in the Abstract. If you are reporting results from 
a controlled health care intervention, please include your trial registry, together with your unique 
identifying number at the end of the Abstract. For randomized controlled trials, follow the CONSORT 




The Introduction section should introduce the topic to readers without specialist knowledge in that 
area and must clearly outline the current state of knowledge in this field, the motivation and the aim 
of the study or the article. 





The Methods section should include all information necessary to repeat the study, in particular, the 
study design, how data was collected and analyzed, clarifying the choice of methods that were 
made. If applicable, you should describe the setting of the study, the dates the study were 
conducted, and the sample or participants, as well as necessary power calculations and materials, 
including statistical packages, used. Interventions and programmes should be described in detail. 
Generic names for drugs or any molecules should be used. 
 
All studies involving humans or animals require a statement on ethical approval, and for the former, 
the consent procedure that was followed. Please include the names of the ethics review board(s) 
that approved the study. If the research study was specific to one sex/gender, the reasons for this 
should be clearly stated. 
 
Results 
This section should include only data and findings from the authors' study. Presentation of statistical 
results should mention confidence intervals and levels of significance where appropriate. Quotes 
from qualitative study participants of less than three lines should be quoted in the text using 
quotation marks. For quotes longer than three lines, place the quote in a separate, indented 
paragraph and introduce it with a colon. No quotation marks are needed in this case. Details of the 
participant can be added in round brackets following the quote, but should not contain identifiable 
information to ensure confidentiality. Clarifications within the quotation should be placed in square 
brackets. 
 
Submitting authors are strongly encouraged to include data disaggregated by sex (and, whenever 
possible, by race) and provide a comprehensive analysis of gender and racial differences. The 
authors should include the number and percentage of men, women and, if appropriate, transgender 
persons who participated in the research study. Anatomical and physiological differences between 
men and women (height, weight, body fat-to-muscle ratios, cell counts, hormonal cycles, etc.), as 
well as social and cultural variables (socio-economic, education, access to care, etc.), should be 
taken into consideration in the presentation of data and/or analysis of the results. 
 
Discussion 
In the Discussion section, you should discuss your main findings and place these within the context 
of the current body of knowledge in the field. Limitations of the study, for example, selection bias, 
can also be discussed, and should address how these influence the results and conclusions. If 
statistically significant differences were found between men and women or between different racial 
or cultural groups in the effects of the studied intervention, the implications, if any, for clinical and/or 
public health should be adequately discussed. 
 
Conclusions 
In your Conclusions section, state your key messages from the study and explain their importance 
and relevance, as well as implications. Future studies and recommendations can be included in this 
section. The conclusions drawn must be strictly based on the data provided. 
 
Conflict of Interest Statement 
Authors will be asked to provide a conflict of interest statement during the submission process. For 
details on what to include in this section, see the ‘Conflict of Interest’ section in the Editorial 
Policies and Ethical Considerations section below. Submitting authors should ensure they liaise 
with all co-authors to confirm agreement with the final statement. 
Authorship 
Please refer to the journal’s Authorship policy in the Editorial Policies and Ethical 
Considerations section for details on author listing eligibility. The individual contributions of each 
author must be specified in the Authors' Contributions section. Please use authors' initials and state 
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that all authors have read and approved the final manuscript. An example of a suitable statement is: 
“S.W., N.J., D.W. and S.S. performed the research. S.W., N.J., H.H. and T.L. designed the research 
study. H.H. and S.S. contributed essential reagents or tools. S.W., N.J. and D.W. analysed the data. 
S.W. and N.J. wrote the paper.” Please see the ‘Authorship’ section in the Editorial Policies and 
Ethical Considerations section below for what constitutes authorship. 
Acknowledgments 
Contributions from anyone who does not meet the criteria for authorship should be listed, with 
permission from the contributor, in an Acknowledgments section. Financial and material support 
should also be mentioned. Thanks to anonymous reviewers are not appropriate. 
References 
All external sources of information should be referenced within the text, the tables and figures, using 
consecutive numbering in square brackets, e.g. [1], [3-5], [3,4]. The references should be up to date 
and adequately reflect the current state of knowledge in the field. Citation bias, for example, by 
country or point of view must be avoided. Numbers of references are unlimited for all article 
categories and should be formatted in standard Vancouver style; see Sample references from 
ICMJE . Unpublished observations, personal communications and manuscripts currently under 
consideration should be cited in the text in round brackets and not in the reference list. 
 
Tables 
They should be supplied as editable files, not pasted as images. Tables should be inserted into the 
text. They should have the header: "Table 1. Title of table". All tables should be cited in the text in 
consecutive order. The tables should not contain colour or shading, and no vertical, visible lines. If 
tables are copied or adapted from another source, permission must be sought by the authors prior to 
publication and these should be clearly cited as such. If a table spans more than one page, authors 
may want to consider uploading the table as an additional file instead. Tables should be self-
contained and complement, not duplicate, information contained in the text. A legend can be 
provided underneath the title, listing any abbreviations or meanings of symbols used. If several 
tables are included, please ensure that symbols are used consistently. Legends should be concise 
but comprehensive – the table, legend, and footnotes must be understandable without reference to 
the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used 
(in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or 
SEM should be identified in the headings. 
Figures 
Figures should be cropped as closely as possible and have the header: "Figure 1. Title of figure". All 
figures need to be cited in the text in consecutive order. 
Although authors are encouraged to send the highest-quality figures possible, for peer-review 
purposes, a wide variety of formats, sizes, and resolutions are accepted. Click here for the basic 
figure requirements for figures submitted with manuscripts for initial peer review, as well as the more 
detailed post-acceptance figure requirements. 
Figure legends should be concise but comprehensive – the figure and its legend must be 
understandable without reference to the text. Include definitions of any symbols used and 
define/explain all abbreviations and units of measurement. If several figures are included, please 
ensure that symbols are used consistently. 
Additional Files 
Appendices 
Appendices will be published after the references. For submission, they should be supplied as 
separate files but referred to in the text. 
Supporting Information 
Supporting information is information that is not essential to the article, but provides greater depth 
and background. It is hosted online and appears without editing or typesetting. It may include tables, 
figures, videos, datasets, etc. Click here for Wiley’s FAQs on supporting information. 
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Note : if data, scripts, or other artefacts used to generate the analyses presented in the paper are 
available via a publicly available data repository, authors should include a reference to the location 
of the material within their paper. 
General Style Points 
The following points provide general advice on formatting and style: 
• Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly and 
the abbreviation is helpful to the reader. Initially, use the word in full, followed by the abbreviation in 
parentheses. Thereafter use the abbreviation only. 
• Acronyms: Acronyms should be used sparingly, and not in headings or in the Abstract. Only 
commonly known acronyms may be used, and they should be spelt out at first use followed by the 
abbreviation in brackets. SI units should be used, with litre and molar being permitted. 
• Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau 
International des Poids et Mesures (BIPM) website here for more information about SI units. 
• Numbers: Numbers under 10 are spelt out, except for: measurements with a unit (8mmol/l); age (6 
weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils). 
• Trade Names: Chemical substances should be referred to by the generic name only. Trade names 
should not be used. Drugs should be referred to by their generic names. If proprietary drugs have 
been used in the study, refer to these by their generic name, mentioning the proprietary name and 
the name and location of the manufacturer in parentheses. 
• Footnotes: Footnotes are not allowed in the text, the information shall be included directly into the 
text, where it fits best, and if these are references, to include in the reference section at the end. 
• Language: All submissions must be in UK English (International) and UN-accepted terminology 
should be followed. No capitalization should be used except for grammatically correct use, official 
names and titles, and abbreviations. 
• General recommendation: Use line spacing of 1.5 and an easily readable font, for example, 
Times New Roman, size 12. Your manuscript should contain line numbers to facilitate editors' and 
reviewers' comments 
Wiley Author Resources 
Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts 
for submission available here . In particular, authors may benefit from referring to Wiley’s best 
practice tips on Writing for Search Engine Optimization . 
Editing, Translation, and Formatting Support: Wiley Editing Services can greatly improve the 
chances of a manuscript being accepted. Offering expert help in English language editing, 
translation, manuscript formatting, and figure preparation, Wiley Editing Services ensures that the 
manuscript is ready for submission. 
5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS 
Editorial Review and Acceptance 
The acceptance criteria for all papers are the quality and originality of the research and its 
significance to journal readership. Except where otherwise stated, manuscripts are single-blind peer 
reviewed, meaning that reviewers remain anonymous to the authors, although the authors' identity is 
known to the reviewers. Papers will only be sent to review if the Editors-in-Chief determine that the 
paper meets the appropriate quality and relevance requirements. 
All manuscripts are reviewed by at least two independent experts with experience in the subject area 
and selected by the Editors. Dedicated statistical reviewers may be used if needed. Reviewers have 
to declare any competing interests to the Editors. Authors can suggest peer reviewers during the 
submission step. Suggested peer reviewers should not have co-authored publications with any of 
the authors during the past five years, should not be current collaborators, and should not be 
members of the same institution. Suggested reviewers will be considered alongside potential 
reviewers identified by the Editorial team. Authors may also request exclusion of individuals as 
potential reviewers: those who have clear competing interests, are close collaborators, or have given 
input into the manuscript previously. 
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The Editors assess revised manuscripts based on whether the authors have adequately addressed 
all comments. Re-reviews are only requested when revisions fall out of the technical expertise of the 
Editors. Further rounds of major revisions are usually not allowed, and manuscripts that have not 
been satisfactorily revised will be rejected. Minor revisions though may be requested as needed. 
 
Wiley's policy on the confidentiality of the review process is available here. 
 
Data Storage and Documentation 
The Journal of the International AIDS Society expects that data supporting the results in the paper 
will be archived in an appropriate public repository. Whenever possible the scripts and other 
artefacts used to generate the analyses presented in the paper should also be publicly archived. 
Exceptions may be granted at the discretion of the editor for sensitive information such as human 
subject data or the location of endangered species. Authors are expected to provide a data 
accessibility statement, including a link to the repository they have used, to accompany their paper. 
 
Protein and nucleotide sequences 
For nucleic acid sequences, protein sequences or atomic coordinates, which are cited in the 
manuscript, and the accession number, together with the database where the information was 
deposited, should be cited in square brackets in the text, for example, [EMBL:AB026295, 
EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, 
PIR:S66116]. Relevant databases are: EMBL Nucleotide Sequence Database (EMBL), DNA Data 
Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein 
Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot). 
 
Mass spectrometry 
Mass spectrometry data should be provided in the mzML format according to the HUPO Protein 
Standards Initiative Mass Spectrometry Standards Working Group guidelines. The data should 
also be deposited in the ProteomeExchange through the PRIDE website, and protein interaction 
data can be deposited through members of the IMEx consortium. 
 
Structures 
Protein structures can be submitted with one of the members of the Worldwide Protein Data Bank. 
Nucleic acid structures can be deposited with the Nucleic Acid Database at Rutgers. Crystal 
structures of organic compounds can be deposited with the Cambridge Crystallographic Data 
Centre. 
 
Chemical structures and assays 
Structures of chemical substances can be deposited with PubChem Substance. Bioactivity screens 
of chemical substances can be deposited with PubChem BioAssay. 
 
Functional genomics data (such as microarray or CHIP-Seq data) 
Please refer to standards proposed by the Functional Genomics Data Society and deposit your 
microarray data in MIAME-compliant format in one of the public repositories, for 
example, ArrayExpress or Gene Expression Omnibus (GEO). Deposition of high-throughput 
functional genomics sequencing data (such as RNA-Seq or ChIP-Seq data) with ArrayExpress or 
GEO in compliance with MINSEQE is also needed. 
Computational modelling 
Please prepare models of biochemical reaction networks using the Systems Biology Markup 
Language and submit your model to the BioModels database, as well as providing it as an 
additional file with your submission. 
 
Plasmids 
Please submit copies of your plasmids as DNA or bacterial stocks with Addgene, a non-profit 
repository, or PlasmID, the Plasmid Information Database at Harvard. 
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Ethical approval – Human and animal studies 
 
Human Studies and Subjects 
For manuscripts reporting medical studies that involve human participants, a statement identifying 
the ethics committee that approved the study and confirmation that the study conforms to recognized 
standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection 
of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice. 
A statement on the ethical aspects, including the consent procedure followed, must be included in 
the Methods section of the manuscript. The Editors may reject manuscripts where the research has 
not been carried out within an ethical framework. Images and information from individual participants 
will only be published where the authors have obtained the individual's free prior informed consent. 
Confidentiality of study participants must be ensured at all stages of research and reporting. Authors 
do not need to provide a copy of the consent form to the publisher; however, in signing the author 
license to publish, authors are required to confirm that consent has been obtained. Wiley has 
a standard patient consent form available for use. 
Animal Studies 
A statement indicating that the protocol and procedures employed were ethically reviewed and 
approved, as well as the name of the body giving approval, must be included in the Methods section 
of the manuscript. Authors are encouraged to adhere to animal research reporting standards, for 
example the The Gold Standard Publication Checklist from Hooijmans and colleagues or 
the ARRIVE reporting guidelines for reporting study design and statistical analysis; experimental 
procedures; experimental animals and housing and husbandry. Authors should also state whether 
experiments were performed in accordance with relevant institutional and national guidelines for the 
care and use of laboratory animals: 
• US authors should cite compliance with the US National Research Council's Guide for the Care 
and Use of Laboratory Animals, the US Public Health Service's Policy on Humane Care and Use 
of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals. 
• UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 
Amendment Regulations (SI 2012/3039). 
• European authors outside the UK should conform to Directive 2010/63/EU. 
Clinical Trial Registration 
The journal requires that clinical trials are prospectively registered in a publicly accessible database 
and clinical trial registration numbers should be included in all papers that report their results. 
Authors are asked to include the name of the trial register and the clinical trial registration number at 
the end of the abstract. If the trial is not registered, or was registered retrospectively, the reasons for 
this should be explained. 
 
Research Reporting Guidelines 
Standard of reporting 
The JIAS endorses international standards of reporting. Please see the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals guidelines produced by ICMJE as a reference 
standard of reporting. Authors are also referred to the EQUATOR network website for further 
information on the available reporting guidelines for health research, and the MIBBI Portal for 
prescriptive checklists for reporting biological and biomedical research where applicable. A number 
of checklists are available for various study designs, including randomized controlled trials 
(CONSORT), interventional trials (SPIRIT), qualitative research (COREQ), systematic reviews 
(PRISMA), observational studies (STROBE), economic evaluations of health interventions 
(CHEERS), meta-analyses of observational studies (MOOSE) and diagnostic / prognostic studies 
(STARD and TRIPOD ). For systematic reviews, an additional file should be provided by the authors 
listing all details concerning the search strategy. Please refer to the Cochrane Reviewers' 
Handbook for an example of how a search strategy should be presented. 
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Guidelines on mutation nomenclature are provided by the Human Genome Variation Society , and 
authors should use the recommended gene name by referring to the appropriate genetic 
nomenclature database, for example, HUGO for human genes, and the International Committee on 
Standardized Genetic Nomenclature for Mice. When describing human phenotypes, please use 
standardized terms, such as those proposed by the Elements of Morphology working group 
(see http://research.nhgri.nih.gov/morphology/index.cgi ). 
Contributions from pharmaceutical companies or other commercial organizations should follow 
the Good Publication Practice guidelinEs for pharmaceutical companies, which also apply to 
any companies or individuals that work on industry-sponsored publications, such as freelance 
writers, contract research organizations and communications companies. 
The JIAS supports international standards of reporting of trials, in particular, prospective registering 
and numbering of clinical trials. Clinical trials are defined by the World Health Organization as all 
phase I to IV trials, which are research studies that prospectively assign human participants or 
groups of humans to one or more health-related interventions to evaluate the effects on health 
outcomes. Trials need to be registered prior to submission in a suitable, publicly available registry. 
Links to existing registries can be found through ICMJE here or through the primary registers that 
participate in the WHO International Clinical Trials Registry Platform. The trial registration 
number should be included as the last line of the manuscript Abstract. 
 
Reporting by gender and race 
Submitting authors shall include data disaggregated by sex (and, whenever possible, by race) and 
provide an analysis of gender and racial differences. The authors should include the number and 
percentage of men, women and, if appropriate, transgender persons, who participated in the 
research study. Anatomical and physiological differences between men and women (height, weight, 
body fat-to-muscle ratios, cell counts, hormonal cycles, etc.), as well as social and cultural variables 
(socio-economic, education, access to care, etc.), should be taken into consideration in the 
presentation of data and/or analysis of the results. If statistically significant differences were found 
between men and women or between different racial or cultural groups in the effects of the studied 
intervention, the implications, if any, for clinical and/or public health should be adequately discussed. 
If the research study was specific to one sex/gender, the reasons for this should be clearly stated. 
Please refer to the SAGER guidelines for more information 
 
Species Names 
Upon its first use in the title, abstract, and text, the common name of a species should be followed 
by the scientific name (genus, species, and authority) in parentheses. For well-known species, 
however, scientific names may be omitted from article titles. If no common name exists in English, 
only the scientific name should be used. 
Genetic Nomenclature 
Sequence variants should be described in the text and tables using both DNA and protein 
designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS 
guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are provided. 
Conflict of Interest 
Authors are required to submit a statement on competing interests, which exist when personal or 
financial relationships with persons or organizations may influence the interpretation of the data or 
how the author's work is presented. For details, see ICMJE's policy on competing interests here. In 
brief, all financial competing interests must be disclosed in this statement (reimbursements, fees, 
funding, salary payments from or ownership of any stocks or shares in an organization that may in 
any way gain or lose financially from the publication of the manuscript, either now or in the future, or 
applications for patents relating to the content of the manuscript), as well as non-financial competing 
interests (such as political, personal, religious, ideological, academic and/or intellectual interests) 
that are related to the work submitted. The competing interest statement should be included in the 
manuscript and will be published in the final article. If no competing interests exist, please state in 
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this section, "The authors declare that they have (or The author declares that he/she has) no 
competing interests." 
Copyright and libel 
Legal responsibility to ensure that no material is published that infringes copyright or that includes 
libellous or defamatory content lies with the Journal of the International AIDS Society's publisher, the 
International AIDS Society. If a manuscript is judged by the journal Editors to include potentially 
libellous content, authors will be requested to adjust wording as necessary. 
Commercial writers and editors 
The involvement of scientific (medical) writers or anyone else who assisted with the preparation of 
the manuscript content should be acknowledged, along with their source of funding, as described in 
the European Medical Writers Association (EMWA) guidelines on the role of medical writers in 
developing peer-reviewed publications. 
Funding 
Authors should list all funding sources in the Acknowledgments section. Authors are responsible for 
the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the 
correct nomenclature: https://www.crossref.org/services/funder-registry/ 
Authorship 
It is understood that all authors listed on submitted manuscripts have read and agreed to its content, 
and meet the authorship requirements as detailed by ICMJE here. The list of authors should 
accurately illustrate who contributed to the work and how. All those listed as authors should qualify 
for authorship according to the following criteria: 
1. Have made substantial contributions to conception and design, or acquisition of data, or analysis 
and interpretation of data; 
2. Have been involved in drafting the manuscript or revising it critically for important intellectual 
content; 
3.Have given final approval of the version to be published. Each author should have participated 
sufficiently in the work to take public responsibility for appropriate portions of the content; and 
4. Have agreed to be accountable for all aspects of the work in ensuring that questions related to the 
accuracy or integrity of any part of the work are appropriately investigated and resolved. 
Each author should have participated sufficiently in the work to take public responsibility for 
appropriate portions of the content. Acquisition of funding, collection of data, or general supervision 
of the research group, alone, does not justify authorship. 
All contributors who do not meet the criteria for authorship should be listed in the Acknowledgements 
section. Examples of those who might be acknowledged include a person who provided purely 
technical help or writing assistance, or a head of department, who provided only general support. 
Prior to submitting the article all authors should agree on the order in which their names will be listed 
in the manuscript. 
Additional Authorship Options: Joint first or senior authorship: In the case of joint first authorship, 
a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ 
or ‘X and Y should be considered joint senior author.’ 
ORCID 
As part of the journal’s commitment to supporting authors at every step of the publishing process, 
the journal requires the submitting author (only) to provide an ORCID iD when submitting a 
manuscript. This takes around 2 minutes to complete. Find more information here. 
Publication Ethics 
This journal is a member of the Committee on Publication Ethics (COPE) and endorses the World 
Association of Medical Editors' (WAME's) Policy Statement on Geopolitical Intrusion on Editorial 
Decisions. Note this journal uses iThenticate’s CrossCheck software to detect instances of 
overlapping and similar text in submitted manuscripts. Any misconduct by authors in reporting their 
data, for example, falsification, will lead to rejection of their manuscript and other consequences 
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decided on by the Editors. Please see COPE and International Committee of Medical Journal Editors 
(ICMJE) for further information on ethical issues in publishing 
Read Wiley’s Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines 
can be found here . 
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